CHARLES RIVER LABORATORIES INTERNATIONAL, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $19.78 million for the 3-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-27 was $19.78M, a 16.02% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-28 was $22.38M, a 70.39% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-27 was $23.27M, a 20.36% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-28 was $17.05M, a 2.79% increase year-over-year.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $71.08M, a 1.71% increase from fiscal 2024.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $69.89M, a 2.99% decline from fiscal 2023.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $72.05M, a 2.13% decline from fiscal 2022.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $73.62M, a 3.00% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-27 | $19.78M 10-Q · filed 2026-08-05 | $42.16M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2026-03-28 | $22.38M 10-Q · filed 2026-08-05 | |||
| 2025-12-27 | $71.08M 10-K · filed 2026-02-18 | |||
| 2025-09-27 | $23.27M 10-Q · filed 2025-11-05 | $40.32M derived: sum of 2 quarters · filed 2026-08-05 | $53.45M derived: sum of 3 quarters · filed 2026-08-05 | |
| 2025-06-28 | $17.05M 10-Q · filed 2026-08-05 | $30.18M derived: sum of 2 quarters · filed 2026-08-05 | ||
| 2025-03-29 | $13.13M 10-Q · filed 2026-08-05 | |||
| 2024-12-28 | $69.89M 10-K · filed 2026-02-18 | |||
| 2024-09-28 | $19.33M 10-Q · filed 2025-11-05 | $35.92M derived: sum of 2 quarters · filed 2025-11-05 | $52.66M derived: sum of 3 quarters · filed 2025-11-05 | |
| 2024-06-29 | $16.59M 10-Q · filed 2025-11-05 | $33.33M derived: sum of 2 quarters · filed 2025-11-05 | ||
| 2024-03-30 | $16.74M 10-Q · filed 2025-11-05 | |||
| 2023-12-30 | $72.05M 10-K · filed 2026-02-18 | |||
| 2023-09-30 | $22.80M 10-Q · filed 2024-11-06 | $39.07M derived: sum of 2 quarters · filed 2024-11-06 | $52.53M derived: sum of 3 quarters · filed 2024-11-06 | |
| 2023-07-01 | $16.27M 10-Q · filed 2024-11-06 | $29.73M derived: sum of 2 quarters · filed 2024-11-06 | ||
| 2023-04-01 | $13.46M 10-Q · filed 2024-11-06 | |||
| 2022-12-31 | $73.62M 10-K · filed 2025-02-19 | |||
| 2022-09-24 | $22.00M 10-Q · filed 2023-11-08 | $36.93M derived: sum of 2 quarters · filed 2023-11-08 | $51.55M derived: sum of 3 quarters · filed 2023-11-08 | |
| 2022-06-25 | $14.93M 10-Q · filed 2023-11-08 | $29.55M derived: sum of 2 quarters · filed 2023-11-08 | ||
| 2022-03-26 | $14.62M 10-Q · filed 2023-11-08 | |||
| 2021-12-25 | $71.47M 10-K · filed 2024-02-14 | |||
| 2021-09-25 | $22.02M 10-Q · filed 2022-11-02 | $39.10M derived: sum of 2 quarters · filed 2022-11-02 | $52.29M derived: sum of 3 quarters · filed 2022-11-02 | |
| 2021-06-26 | $17.08M 10-Q · filed 2022-11-02 | $30.27M derived: sum of 2 quarters · filed 2022-11-02 | ||
| 2021-03-27 | $13.19M 10-Q · filed 2022-11-02 | |||
| 2020-12-26 | $56.34M 10-K · filed 2023-02-22 | |||
| 2020-09-26 | $16.87M 10-Q · filed 2021-11-03 | $30.01M derived: sum of 2 quarters · filed 2021-11-03 | $40.97M derived: sum of 3 quarters · filed 2021-11-03 | |
| 2020-06-27 | $13.14M 10-Q · filed 2021-11-03 | $24.10M derived: sum of 2 quarters · filed 2021-11-03 | ||
| 2020-03-28 | $10.96M 10-Q · filed 2021-11-03 | |||
| 2019-12-28 | $57.27M 10-K · filed 2022-02-16 | |||
| 2019-09-28 | $14.03M 10-Q · filed 2020-10-29 | $30.53M derived: sum of 2 quarters · filed 2020-10-29 | $43.43M derived: sum of 3 quarters · filed 2020-10-29 | |
| 2019-06-29 | $16.50M 10-Q · filed 2020-10-29 | $29.40M derived: sum of 2 quarters · filed 2020-10-29 | ||
| 2019-03-30 | $12.90M 10-Q · filed 2020-10-29 | |||
| 2018-12-29 | $47.35M 10-K · filed 2021-02-17 | |||
| 2018-09-29 | $11.82M 10-Q · filed 2019-11-06 | $25.37M derived: sum of 2 quarters · filed 2019-11-06 | $35.91M derived: sum of 3 quarters · filed 2019-11-06 | |
| 2018-06-30 | $13.55M 10-Q · filed 2019-11-06 | $24.09M derived: sum of 2 quarters · filed 2019-11-06 | ||
| 2018-03-31 | $10.54M 10-Q · filed 2019-11-06 | |||
| 2017-12-30 | $44.00M 10-K · filed 2020-02-11 | |||
| 2016-12-31 | $43.64M 10-K · filed 2019-02-13 | |||
| 2015-12-26 | $40.12M 10-K · filed 2018-02-13 | |||
| 2014-12-27 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-14 | $16.15M derived: sum of 2 quarters · filed 2017-02-14 | $24.38M derived: sum of 3 quarters · filed 2017-02-14 | $31.04M 10-K · filed 2017-02-14 |
| 2014-09-27 | $8.25M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $16.47M derived: sum of 2 quarters · filed 2014-10-30 | $23.13M 10-Q · filed 2014-10-30 | $29.44M derived: sum of 4 quarters · filed 2014-10-30 |
| 2014-06-28 | $8.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | $14.88M 10-Q · filed 2014-08-07 | $21.19M derived: sum of 3 quarters · filed 2014-08-07 | $27.24M derived: sum of 4 quarters · filed 2014-08-07 |
| 2014-03-29 | $6.66M 10-Q · filed 2014-04-30 | $12.97M derived: sum of 2 quarters · filed 2014-04-30 | $19.02M derived: sum of 3 quarters · filed 2014-04-30 | $25.30M derived: sum of 4 quarters · filed 2014-04-30 |
| 2013-12-28 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $12.36M derived: sum of 2 quarters · filed 2014-02-25 | $18.64M derived: sum of 3 quarters · filed 2014-02-25 | $24.54M 10-K · filed 2014-02-25 |
| 2013-09-28 | $6.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-10-30 | $12.33M derived: sum of 2 quarters · filed 2013-10-30 | $18.23M 10-Q · filed 2013-10-30 | $24.26M derived: sum of 4 quarters · filed 2014-02-25 |
| 2013-06-29 | $6.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-07-31 | $12.18M 10-Q · filed 2013-07-31 | $18.21M derived: sum of 3 quarters · filed 2014-02-25 | $23.45M derived: sum of 4 quarters · filed 2014-02-25 |
| 2013-03-30 | $5.90M 10-Q · filed 2013-05-08 | $11.93M derived: sum of 2 quarters · filed 2014-02-25 | $17.17M derived: sum of 3 quarters · filed 2014-02-25 | $22.49M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-12-29 | $6.03M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $11.27M derived: sum of 2 quarters · filed 2014-02-25 | $16.59M derived: sum of 3 quarters · filed 2014-02-25 | $21.86M 10-K · filed 2014-02-25 |
| 2012-09-29 | $5.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-01 | $10.56M derived: sum of 2 quarters · filed 2012-11-01 | $15.83M 10-Q · filed 2012-11-01 | $20.61M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-06-30 | $5.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $10.59M 10-Q · filed 2012-08-07 | $15.37M derived: sum of 3 quarters · filed 2014-02-25 | $20.94M derived: sum of 4 quarters · filed 2014-02-25 |
| 2012-03-31 | $5.27M 10-Q · filed 2012-05-04 | $10.05M derived: sum of 2 quarters · filed 2014-02-25 | $15.62M derived: sum of 3 quarters · filed 2014-02-25 | $21.05M derived: sum of 4 quarters · filed 2014-02-25 |
| 2011-12-31 | $4.79M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-25 | $10.36M derived: sum of 2 quarters · filed 2014-02-25 | $15.79M derived: sum of 3 quarters · filed 2014-02-25 | $21.71M 10-K · filed 2014-02-25 |
| 2011-09-24 | $5.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $11.00M derived: sum of 2 quarters · filed 2011-11-02 | $16.92M 10-Q · filed 2011-11-02 | $21.21M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-06-25 | $5.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2011-08-03 | $11.35M 10-Q · filed 2011-08-03 | $15.64M derived: sum of 3 quarters · filed 2013-02-27 | $22.41M derived: sum of 4 quarters · filed 2013-02-27 |
| 2011-03-26 | $5.92M 10-Q · filed 2011-05-04 | $10.21M derived: sum of 2 quarters · filed 2013-02-27 | $16.98M derived: sum of 3 quarters · filed 2013-02-27 | |
| 2010-12-25 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-27 | $11.06M derived: sum of 2 quarters · filed 2013-02-27 | $25.74M 10-K · filed 2013-02-27 | |
| 2010-09-25 | $6.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-02 | $21.44M 10-Q · filed 2011-11-02 | ||
| 2010-06-26 | $14.67M 10-Q · filed 2011-08-03 | |||
| 2009-12-26 | $23.81M 10-K · filed 2012-02-27 | |||
| 2008-12-27 | $24.33M 10-K · filed 2011-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |